Kiniksa Pharmaceuticals, Ltd. (KNSA)

Market Cap	795.88M
Revenue (ttm)	220.18M
Net Income (ttm)	183.36M
Shares Out	69.75M
EPS (ttm)	2.60
PE Ratio	4.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	232,554
Open	11.22
Previous Close	11.23
Day's Range	10.76 - 11.47
52-Week Range	7.36 - 17.20
Beta	-0.08
Analysts	Buy
Price Target	21.42 (+87.73%)
Earnings Date	May 2, 2023

About KNSA

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arter...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 24, 2018
• Employees: 215
• Stock Exchange: NASDAQ
• Ticker Symbol: KNSA

Analyst Forecast

According to 11 analysts, the average rating for KNSA stock is "Buy." The 12-month stock price forecast is $21.42, which is an increase of 87.73% from the latest price.

Price Target

$21.42

(87.73% upside)

Analyst Consensus: Buy